Loading...
Please wait, while we are loading the content...
Similar Documents
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
Content Provider | MDPI |
---|---|
Author | Thuru, Xavier Magnez, Romain El-Bouazzati, Hassiba Vergoten, Gérard Quesnel, Bruno Bailly, Christian |
Copyright Year | 2022 |
Description | Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have considerably improved the treatment of some cancers, but novel drugs, new combinations, and treatment modalities are needed to reinvigorate immunosurveillance in immune-refractory tumors. An option to elicit antitumor immunity against cancer consists of using approved and marketed drugs known for their capacity to modulate the expression and functioning of the PD-1/PD-L1 checkpoint. Here, we have reviewed several types of drugs known to alter the checkpoint, either directly via the blockade of PD-L1 or indirectly via an action on upstream effectors (such as STAT3) to suppress PD-L1 transcription or to induce its proteasomal degradation. Specifically, the repositioning of the approved drugs liothyronine, azelnidipine (and related dihydropyridine calcium channel blockers), niclosamide, albendazole/flubendazole, and a few other modulators of the PD-1/PD-L1 checkpoint (repaglinide, pimozide, fenofibrate, lonazolac, propranolol) is presented. Their capacity to bind to PD-L1 or to repress its expression and function offer novel perspectives for combination with PD-1 targeted biotherapeutics. These known and affordable drugs could be useful to improve the therapy of cancer. |
Starting Page | 3368 |
e-ISSN | 20726694 |
DOI | 10.3390/cancers14143368 |
Journal | Cancers |
Issue Number | 14 |
Volume Number | 14 |
Language | English |
Publisher | MDPI |
Publisher Date | 2022-07-11 |
Access Restriction | Open |
Subject Keyword | Cancers Oncology Azelnidipine Cancer Therapy Drug Repurposing Immune Checkpoint Liothyronine Niclosamide Pd-1 Pd-l1 Tumor |
Content Type | Text |
Resource Type | Article |